EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada

Kevin R Barker iD, Gabriel W Rebick, Ken Fakharuddin, Clayton MacDonald, Michael R Mulvey, Laura F Mataseje iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.03223-23 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Kevin R Barker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology, Department of Laboratory Medicine and Genetics, Trillium Health Partners, Mississauga, Ontario, Canada. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Escherichia coli Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Agency of Canada (PHAC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gram-negative metallo-β-lactamase-producing bacteria can be extremely problematic, especially when found to be extensively drug-resistant (XDR). Cefiderocol is a novel antimicrobial that has been shown to overcome most carbapenemases, with very rare resistance reported to date. Within our institution, two multidrug-resistant and one XDR strains were isolated from a patient who recently emigrated from India. Each isolate underwent whole-genome sequencing to resolve plasmids and determine phylogenetics, strain typing, and mechanisms of resistance. The XDR E. coli was ST167, harbored NDM-5, cirA and PBP3 mutations, consistent with cefiderocol resistance. Our study suggests that the NDM region is required in conjunction with cirA and PBP3 mutations. It is not clear why; however, our study did determine a potential novel iron-transport region unique to the cefiderocol-resistant isolate. This is the first characterized cefiderocol-resistant E.coli reported from Canada. Health centers should be on alert for this clone. IMPORTANCE The development of cefiderocol, a novel siderophore cephalosporin, has provided additional options to the treatment of extensively drug-resistant (XDR) Gram-negative bacteria. Resistance to cefiderocol is poorly understood and only recently described. Here, we describe a case of a patient with recent travel to India harboring three Escherichia coli isolates, one resistant and two susceptible to cefiderocol. Two isolates are highly similar genetically, allowing the mechanism of resistance to be described more closely. The importance of this manuscript contributes both globally to the understanding of cefiderocol resistance in E. coli as well as nationally as this is the first resistant case reported in Canada. This is especially concerning as cefiderocol is not currently approved in Canada. The implications of reporting emerging resistance to new antimicrobials for XDR Gram negatives are impactful to infectious disease specialists, clinical microbiologists, physicians, and public health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialEscherichia coli InfectionsHumansMalebeta-LactamasesCanadaCefiderocolCephalosporinsEscherichia coliEscherichia coli ProteinsIndiaMicrobial Sensitivity TestsMutationPhylogenyPlasmidsWhole Genome SequencingAged

Stichwörter der Autor:innen

CanadaST167XDRantimicrobial resistancecarbapenem-resistant Enterobacteriaceaecarbapenemasecefiderocolextensively drug-resistant

Substanzen

Anti-Bacterial Agentsbeta lactamase NDM-5, E colibeta-LactamasesCefiderocolCephalosporinsEscherichia coli Proteins

Autor:innen und Institutionen

  • Microbiology, Department of Laboratory Medicine and Genetics, Trillium Health Partners, Mississauga, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada.
  • Division of Infectious Diseases, Department of Medicine, Trillium Health Partners, Mississauga, Ontario, Canada.
  • Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Canada.

ORCID-Profile: Kevin R Barker, Laura F Mataseje

Förderung

  • Public Health Agency of Canada (PHAC)

Zitieren

APA

Barker, K. R., Rebick, G. W., Fakharuddin, K., MacDonald, C., Mulvey, M. R., & Mataseje, L. F. (2024). When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03223-23

Vancouver

Barker KR, Rebick GW, Fakharuddin K, MacDonald C, Mulvey MR, Mataseje LF. When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada. Microbiology Spectrum. 2024. doi:10.1128/spectrum.03223-23

BibTeX
@article{Barker2024,
  author = {Barker, Kevin R and Rebick, Gabriel W and Fakharuddin, Ken and MacDonald, Clayton and Mulvey, Michael R and Mataseje, Laura F},
  title = {When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.03223-23}
}
Kostenlos starten →